About Abiomed (NASDAQ:ABMD)
ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. It also manufactures and sells AB5000 circulatory support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, the company engages in the research, development, prototyping, and the pre-serial production of a percutaneous expandable catheter pump, which enhances blood circulation from the heart with an external drive shaft. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. ABIOMED, Inc. was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400
Debt
Debt-to-Equity RatioN/A
Current Ratio5.60%
Quick Ratio4.98%
Price-To-Earnings
Trailing P/E Ratio261.54
Forward P/E Ratio136.00
P/E Growth3.02
Sales & Book Value
Annual Sales$445.30 million
Price / Sales30.43
Cash Flow$1.3323 per share
Price / Cash229.68
Book Value$10.38 per share
Price / Book29.48
Profitability
EPS (Most Recent Fiscal Year)$1.17
Net Income$52.11 million
Net Margins16.58%
Return on Equity15.54%
Return on Assets13.40%
Miscellaneous
Employees908
Outstanding Shares44,280,000
Abiomed (NASDAQ:ABMD) Frequently Asked Questions
What is Abiomed's stock symbol?
Abiomed trades on the NASDAQ under the ticker symbol "ABMD."
How were Abiomed's earnings last quarter?
Abiomed (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, February, 1st. The medical equipment provider reported $0.70 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.50 by $0.20. The medical equipment provider earned $154 million during the quarter, compared to the consensus estimate of $154 million. Abiomed had a net margin of 16.58% and a return on equity of 15.54%. The firm's revenue was up 34.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.34 EPS. View Abiomed's Earnings History.
When is Abiomed's next earnings date?
What price target have analysts set for ABMD?
9 Wall Street analysts have issued 12-month price targets for Abiomed's shares. Their forecasts range from $259.00 to $370.00. On average, they expect Abiomed's share price to reach $305.8571 in the next year. View Analyst Ratings for Abiomed.
Who are some of Abiomed's key competitors?
Some companies that are related to Abiomed include ResMed (RMD), Teleflex (TFX), Dexcom (DXCM), Hill-Rom (HRC), Insulet (PODD), ICU Medical (ICUI), Globus Medical (GMED), Cantel Medical (CMD), Penumbra (PEN), Haemonetics (HAE), Nevro (NVRO), NuVasive (NUVA), Merit Medical Systems (MMSI), NovoCure (NVCR), Mazor Robotics (MZOR), Irhythm Technologies (IRTC), Intersect ENT (XENT) and ATRION (ATRI).
Who are Abiomed's key executives?
Abiomed's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, Chief Exec. Officer and Pres (Age 51)
- Dr. David M. Weber Ph.D., Chief Operating Officer (Age 57)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 54)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 66)
- Dr. Thorsten Siess, Chief Technology Officer
Has Abiomed been receiving favorable news coverage?
Media headlines about ABMD stock have trended somewhat positive on Friday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Abiomed earned a news impact score of 0.23 on Accern's scale. They also gave media headlines about the medical equipment provider an impact score of 44.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Abiomed's major shareholders?
Abiomed's stock is owned by a number of of retail and institutional investors. Top institutional investors include
PRIMECAP MANAGEMENT COMPANY
(9.23%) and
PRIMECAP MANAGEMENT COMPANY
(9.23%). Company insiders that own Abiomed stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue and Paul Thomas. View Institutional Ownership Trends for Abiomed.
How do I buy shares of Abiomed?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abiomed's stock price today?
One share of ABMD stock can currently be purchased for approximately $305.92.
How big of a company is Abiomed?
Abiomed has a market capitalization of $13.62 billion and generates $445.30 million in revenue each year. The medical equipment provider earns $52.11 million in net income (profit) each year or $1.17 on an earnings per share basis. Abiomed employs 908 workers across the globe.
How can I contact Abiomed?
Abiomed's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for Abiomed (ABMD)
MarketBeat's community ratings are surveys of what our community members think about Abiomed and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abiomed (NASDAQ:ABMD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
9 Wall Street analysts have issued ratings and price targets for Abiomed in the last 12 months. Their average twelve-month price target is $305.8571, suggesting that the stock has a possible downside of 0.05%. The high price target for ABMD is $370.00 and the low price target for ABMD is $259.00. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.78 | 2.75 | 2.71 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $305.8571 | $301.50 | $210.00 | $174.7143 |
| Price Target Upside: | 0.05% downside | 12.61% upside | 7.03% downside | 0.50% upside |
Abiomed (NASDAQ:ABMD) Consensus Price Target History
Abiomed (NASDAQ:ABMD) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Abiomed (NASDAQ:ABMD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Abiomed (NASDAQ ABMD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 88.41%
Abiomed (NASDAQ ABMD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 2/20/2018 | Andrew J Greenfield | VP | Sell | 20,000 | $270.36 | $5,407,200.00 | |  |
| 10/30/2017 | Dorothy E Puhy | Director | Sell | 6,364 | $179.08 | $1,139,665.12 | 39,532 | |
| 10/30/2017 | Michael G Howley | VP | Sell | 10,000 | $178.64 | $1,786,400.00 | 56,757 | |
| 10/2/2017 | Andrew J Greenfield | VP | Sell | 11,282 | $169.32 | $1,910,268.24 | | |
| 8/30/2017 | Eric A Md Rose | Director | Sell | 982 | $145.17 | $142,556.94 | 13,634 | |
| 8/24/2017 | Eric A Md Rose | Director | Sell | 23,018 | $151.09 | $3,477,789.62 | 24,652 | |
| 8/15/2017 | Paul Thomas | Director | Sell | 10,000 | $154.71 | $1,547,100.00 | 12,172 | |
| 7/31/2017 | David M Weber | COO | Sell | 16,500 | $147.63 | $2,435,895.00 | 125,122 | |
| 5/16/2017 | Michael G Howley | VP | Sell | 18,279 | $133.56 | $2,441,343.24 | 62,105 | |
| 5/8/2017 | David M Weber | COO | Sell | 21,250 | $130.89 | $2,781,412.50 | 123,771 | |
| 5/8/2017 | Dorothy E Puhy | Director | Sell | 13,500 | $131.12 | $1,770,120.00 | 38,249 | |
| 5/8/2017 | Michael G Howley | VP | Sell | 600 | $132.84 | $79,704.00 | 48,305 | |
| 3/17/2017 | Andrew J Greenfield | VP | Sell | 10,000 | $124.00 | $1,240,000.00 | 66,307 | |
| 12/13/2016 | Dorothy E Puhy | Director | Sell | 8,000 | $120.00 | $960,000.00 | 32,749 | |
| 11/30/2016 | Eric A Md Rose | Director | Sell | 8,000 | $110.81 | $886,480.00 | 21,259 | |
| 9/22/2016 | Michael R Minogue | CEO | Sell | 28,039 | $127.07 | $3,562,915.73 | 215,488 | |
| 9/21/2016 | Michael R Minogue | CEO | Sell | 5,034 | $127.07 | $639,670.38 | 215,782 | |
| 9/19/2016 | Michael R Minogue | CEO | Sell | 58,710 | $127.00 | $7,456,170.00 | 215,782 | |
| 8/15/2016 | Dorothy E Puhy | Director | Sell | 5,160 | $123.94 | $639,530.40 | 24,749 | |
| 8/10/2016 | Dorothy E Puhy | Director | Sell | 3,900 | $122.31 | $477,009.00 | 33,811 | |
| 8/8/2016 | Michael G Howley | VP | Sell | 17,853 | $119.20 | $2,128,077.60 | 65,558 | |
| 8/1/2016 | Henri A Termeer | Director | Sell | 25,866 | $118.70 | $3,070,294.20 | 325,778 | |
| 6/29/2016 | Michael G Howley | VP | Sell | 10,000 | $106.58 | $1,065,800.00 | 65,558 | |
| 6/7/2016 | Andrew J Greenfield | VP | Sell | 9,000 | $104.16 | $937,440.00 | 65,234 | |
| 5/23/2016 | David M Weber | COO | Sell | 4,342 | $96.97 | $421,043.74 | 100,159 | |
| 5/16/2016 | David M Weber | COO | Sell | 5,604 | $94.56 | $529,914.24 | 116,783 | |
| 5/6/2016 | David M Weber | COO | Sell | 2,145 | $93.82 | $201,243.90 | 117,411 | |
| 5/5/2016 | David M Weber | COO | Sell | 52,000 | $95.27 | $4,954,040.00 | 121,676 | |
| 5/5/2016 | Paul Thomas | Director | Sell | 7,500 | $95.14 | $713,550.00 | 28,811 | |
| 4/18/2016 | Andrew J Greenfield | VP | Sell | 10,000 | $99.10 | $991,000.00 | 61,186 | |
| 4/13/2016 | Michael G Howley | VP | Sell | 9,800 | $98.64 | $966,672.00 | 62,268 | |
| 4/8/2016 | Michael G Howley | VP | Sell | 200 | $98.80 | $19,760.00 | 52,668 | |
| 4/1/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $95.02 | $950,200.00 | 47,792 | |
| 3/31/2016 | Andrew J Greenfield | VP | Sell | 15,000 | $94.11 | $1,411,650.00 | 58,941 | |
| 3/24/2016 | David M Weber | COO | Sell | 5,235 | $89.93 | $470,783.55 | 113,411 | |
| 3/22/2016 | Andrew J Greenfield | VP | Sell | 24,800 | $89.06 | $2,208,688.00 | 73,614 | |
| 3/22/2016 | Dorothy E Puhy | Director | Sell | 10,000 | $90.30 | $903,000.00 | 52,190 | |
| 3/21/2016 | Andrew J Greenfield | VP | Sell | 19,572 | $89.07 | $1,743,278.04 | 73,614 | |
| 3/10/2016 | Andrew J Greenfield | VP | Sell | 200 | $89.00 | $17,800.00 | 54,242 | |
| 3/8/2016 | David M Weber | COO | Sell | 17,521 | $85.20 | $1,492,789.20 | 125,761 | |
| 3/8/2016 | William J Bolt | SVP | Sell | 17,510 | $85.19 | $1,491,676.90 | 98,392 | |
| 3/7/2016 | David M Weber | COO | Sell | 8,111 | $85.21 | $691,138.31 | 125,761 | |
| 3/7/2016 | Dorothy E Puhy | Director | Sell | 4,000 | $85.00 | $340,000.00 | 66,190 | |
| 3/7/2016 | William J Bolt | SVP | Sell | 7,987 | $85.20 | $680,492.40 | 98,392 | |
| 2/8/2016 | Dorothy E. Puhy | Director | Sell | 4,000 | $80.47 | $321,880.00 | 62,190 | |
| 8/19/2015 | Michael R. Minogue | CEO | Sell | 146,800 | $104.87 | $15,394,916.00 | 239,718 | |
| 8/17/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $103.91 | $268,087.80 | | |
| 8/14/2015 | Dorothy E Puhy | Director | Sell | 2,580 | $105.27 | $271,596.60 | | |
| 7/17/2015 | Michael G Howley | VP | Sell | 21,295 | $70.00 | $1,490,650.00 | | |
| 6/15/2015 | Andrew J Greenfield | VP | Sell | 3,185 | $65.00 | $207,025.00 | | |
| 5/29/2015 | Martin P Sutter | Director | Buy | 7,500 | $60.17 | $451,275.00 | | |
| 5/27/2015 | David M Weber | COO | Sell | 17,968 | $60.77 | $1,091,915.36 | | |
| 5/12/2015 | Michael G Howley | VP | Sell | 17,353 | $66.47 | $1,153,453.91 | | |
| 5/7/2015 | Andrew J Greenfield | VP | Sell | 3,500 | $71.00 | $248,500.00 | | |
| 5/7/2015 | Robert Bowen | CFO | Sell | 2,372 | $71.52 | $169,645.44 | | |
| 5/6/2015 | David M Weber | COO | Sell | 1,605 | $73.72 | $118,320.60 | | |
| 5/6/2015 | Michael R Minogue | CEO | Sell | 8,840 | $73.12 | $646,380.80 | | |
| 5/6/2015 | William J Bolt | SVP | Sell | 1,750 | $74.27 | $129,972.50 | | |
| 3/23/2015 | David M Weber | COO | Sell | 3,765 | $71.08 | $267,616.20 | | |
| 10/31/2014 | Andrew J Greenfield | VP | Sell | 15,000 | $31.90 | $478,500.00 | | |
| 10/31/2014 | Michael R Minogue | CEO | Sell | 164,000 | $31.14 | $5,106,960.00 | | |
| 7/28/2014 | Michael R Minogue | CEO | Sell | 82,383 | $26.30 | $2,166,672.90 | | |
| 5/27/2014 | Andrew J Greenfield | VP | Sell | 7,026 | $21.10 | $148,248.60 | | |
| 5/27/2014 | David M Weber | COO | Sell | 10,172 | $21.11 | $214,730.92 | | |
| 5/27/2014 | Michael R Minogue | CEO | Sell | 90,001 | $21.19 | $1,907,121.19 | | |
| 5/27/2014 | Robert Bowen | CFO | Sell | 6,820 | $21.11 | $143,970.20 | | |
| 5/27/2014 | William J Bolt | SVP | Sell | 8,029 | $21.10 | $169,411.90 | | |
| 5/15/2014 | David Weber | COO | Sell | 1,425 | $20.94 | $29,839.50 | 130,482 | |
| 5/15/2014 | Michael Howley | VP | Sell | 1,267 | $20.94 | $26,530.98 | 74,486 | |
| 5/15/2014 | Michael Minogue | CEO | Sell | 4,433 | $20.94 | $92,827.02 | 260,912 | |
| 5/15/2014 | William Bolt | SVP | Sell | 1,110 | $20.94 | $23,243.40 | 94,205 | |
| 1/10/2014 | Robert Bowen | CFO | Sell | 37,500 | $30.00 | $1,125,000.00 | 66,929 | |
| 9/3/2013 | David Weber | COO | Sell | 6,500 | $24.00 | $156,000.00 | 126,907 | |
| 9/3/2013 | William Bolt | SVP | Sell | 20,000 | $24.00 | $480,000.00 | 89,718 | |
| 8/14/2013 | William Bolt | SVP | Sell | 21,534 | $23.35 | $502,818.90 | 89,718 | |
| 8/13/2013 | David Weber | COO | Sell | 4,400 | $23.00 | $101,200.00 | 133,407 | |
| 8/13/2013 | Michael Howley | VP | Sell | 8,400 | $23.00 | $193,200.00 | 68,753 | |
| 8/5/2013 | David Weber | COO | Sell | 7,100 | $22.90 | $162,590.00 | 137,807 | |
| 8/5/2013 | Michael Howley | VP | Sell | 1,600 | $23.03 | $36,848.00 | 77,153 | |
| 8/5/2013 | Robert Bowen | CFO | Sell | 2,235 | $22.64 | $50,600.40 | 66,929 | |
| 8/5/2013 | W Gerald Austen | Director | Sell | 8,000 | $22.85 | $182,800.00 | | |
| 8/5/2013 | William Bolt | SVP | Sell | 20,166 | $22.70 | $457,768.20 | 98,552 | |
| 7/31/2013 | Michael R Minogue | CEO | Sell | 36,500 | $25.04 | $913,960.00 | | |
| 7/17/2013 | Michael G Howley | VP | Sell | 10,000 | $24.45 | $244,500.00 | | |
| 7/15/2013 | Robert Bowen | CFO | Sell | 40,786 | $23.50 | $958,471.00 | | |
| 7/11/2013 | Robert Bowen | CFO | Sell | 1,499 | $23.50 | $35,226.50 | | |
| 6/4/2013 | David M Weber | COO | Sell | 6,519 | $21.20 | $138,202.80 | | |
| 6/4/2013 | Michael G Howley | VP | Sell | 3,881 | $21.20 | $82,277.20 | | |
| 6/4/2013 | Michael R Minogue | CEO | Sell | 17,667 | $21.23 | $375,070.41 | | |
| 6/4/2013 | Robert Bowen | CFO | Sell | 5,298 | $21.20 | $112,317.60 | | |
| 6/4/2013 | William J Bolt | SVP | Sell | 4,967 | $21.20 | $105,300.40 | | |
| 5/29/2013 | Michael R Minogue | CEO | Sell | 58,833 | $21.83 | $1,284,324.39 | | |
| 5/28/2013 | David M Weber | COO | Sell | 6,018 | $22.18 | $133,479.24 | | |
| 5/28/2013 | Michael G Howley | VP | Sell | 5,476 | $22.18 | $121,457.68 | | |
| 5/28/2013 | Robert Bowen | CFO | Sell | 5,102 | $22.18 | $113,162.36 | | |
| 5/28/2013 | William J Bolt | SVP | Sell | 4,629 | $22.18 | $102,671.22 | | |
| 5/23/2013 | Andrew J Greenfield | VP | Sell | 1,666 | $21.63 | $36,035.58 | | |
| 5/23/2013 | Michael R Minogue | CEO | Sell | 5,666 | $21.62 | $122,498.92 | | |
| 5/17/2013 | Robert Bowen | CFO | Sell | 2,715 | $23.50 | $63,802.50 | | |
| 5/9/2013 | Michael R Minogue | CEO | Sell | 20,000 | $21.00 | $420,000.00 | | |
| 5/7/2013 | Henri A Termeer | Director | Buy | 100,000 | $19.86 | $1,986,000.00 | | |
| 2/25/2013 | Henri A Termeer | Director | Buy | 100,000 | $14.98 | $1,498,000.00 | | |
(Data available from 1/1/2013 forward)
Abiomed (NASDAQ ABMD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Abiomed (ABMD) Given a $145.00 Price Target by Piper Jaffray Analysts
www.americanbankingnews.com - April 19 at 11:52 PM |
 | Can Neurotechnology & Spine Drive Stryker (SYK) Q1 Earnings?
finance.yahoo.com - April 17 at 9:52 AM |
| Abiomed (ABMD) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - April 16 at 12:02 PM |
| Abiomed (ABMD) Expected to Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - April 14 at 4:17 AM |
 | Artificial Organs Global Market Forecast to 2023 - Market Projected to Reach $21 Billion Growing at a CAGR of 9.5%
www.prnewswire.com - April 13 at 10:04 AM |
| Abiomed Fourth Quarter Fiscal 2018 Earnings and Conference Call Notification
finance.yahoo.com - April 13 at 10:04 AM |
| Quick Profits In This Swing Trade Were Fueled By Stock Market Rally
finance.yahoo.com - April 13 at 10:04 AM |
 | Global Artificial Organs Market 2018-2023 with Key Players Abiomed, Heartware, Edwards Lifesciences Corp, Boston ...
www.businesswire.com - April 12 at 4:19 PM |
| $0.64 Earnings Per Share Expected for Abiomed (ABMD) This Quarter
www.americanbankingnews.com - April 12 at 9:19 AM |
| BidaskClub Upgrades Abiomed (ABMD) to "Buy"
www.americanbankingnews.com - April 10 at 10:30 PM |
| Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Abbott Laboratories, ABIOMED, Align ...
www.prnewswire.com - April 9 at 10:11 AM |
 | UPDATE: ABIOMED (ABMD) PT Raised to $300 at Stephens
www.streetinsider.com - April 9 at 10:11 AM |
 | ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe
www.nasdaq.com - April 5 at 4:14 PM |
| ABIOMED's (ABMD) Impella 5.5 Receives CE Mark in Europe
finance.yahoo.com - April 5 at 4:14 PM |
| Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart ...
www.nasdaq.com - April 5 at 8:50 AM |
| Abiomed Announces European Approval (CE Marking) for Impella 5.5(TM) and First Patient Treated at University Heart Center Hamburg
finance.yahoo.com - April 5 at 8:50 AM |
| Here's Why You Should Invest in ABIOMED (ABMD) Right Now
www.nasdaq.com - April 4 at 5:14 PM |
 | The 3 Most Expensive Large Healthcare Stocks on the Market: Are They Worth Their Hefty Price Tags?
www.fool.com - April 4 at 5:14 PM |
 | Abiomed Announces European Approval (CE Marking) for Impella 5.5™ and First Patient Treated at University Heart ...
globenewswire.com - April 4 at 5:14 PM |
| ABIOMED (ABMD) Research Coverage Started at Goldman Sachs
www.americanbankingnews.com - April 4 at 8:04 AM |
| Zacks Investment Research Upgrades ABIOMED (ABMD) to "Buy"
www.americanbankingnews.com - April 4 at 12:34 AM |
| ABIOMED (ABMD) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 3 at 8:12 PM |
| FDA Nod for Abiomed Impella CP with SmartAssist Widens Suite
finance.yahoo.com - April 3 at 4:22 PM |
| ABIOMED (ABMD) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - April 3 at 10:07 AM |
| ABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 31 at 8:11 AM |
| ABIOMED's (ABMD) Buy Rating Reaffirmed at Piper Jaffray
www.americanbankingnews.com - March 30 at 4:32 PM |
 | BRIEF-Abiomed To Appoint Todd Trapp Chief Financial Officer
www.reuters.com - March 30 at 9:53 AM |
| Abiomed to Appoint New Chief Financial Officer Todd A. Trapp
finance.yahoo.com - March 30 at 9:53 AM |
| Watts Water CFO to leave for 'new opportunity' at Abiomed
finance.yahoo.com - March 30 at 9:53 AM |
| ABIOMED (ABMD) Raised to Buy at BidaskClub
www.americanbankingnews.com - March 28 at 9:48 PM |
| Analysts Anticipate ABIOMED, Inc. (ABMD) Will Announce Quarterly Sales of $163.84 Million
www.americanbankingnews.com - March 28 at 9:25 AM |
 | Lawsuit: Abiomed fired exec to avoid huge stock payout
www.bizjournals.com - March 26 at 4:19 PM |
| $0.64 Earnings Per Share Expected for ABIOMED, Inc. (ABMD) This Quarter
www.americanbankingnews.com - March 26 at 11:14 AM |
| ABIOMED (ABMD) and Cogentix Medical (CGNT) Financial Contrast
www.americanbankingnews.com - March 23 at 5:16 AM |
| MDY, SIVB, TTWO, ABMD: Large Outflows Detected at ETF - Nasdaq
www.nasdaq.com - March 21 at 4:25 PM |
| ABIOMED (ABMD) Banks on Impella Platform, Competition Rife
finance.yahoo.com - March 13 at 11:24 AM |
| Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Quarterly Sales of $163.84 Million
www.americanbankingnews.com - March 11 at 8:50 AM |
| Is It Too Late To Buy ABIOMED Inc (NASDAQ:ABMD)?
finance.yahoo.com - March 10 at 10:43 AM |
| Feds say heart pump maker Abiomed wooed doctors with 'lavish' meals, booze
finance.yahoo.com - March 8 at 4:22 PM |
| Abiomed to pay $3.1 mln to settle case over lavish doctor meals
finance.yahoo.com - March 8 at 4:22 PM |
| Why Abiomed Soared 14.1% In February
finance.yahoo.com - March 8 at 11:03 AM |
| ABIOMED, Inc. (ABMD) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 6 at 1:38 PM |
| 17,556 Shares in ABIOMED, Inc. (ABMD) Acquired by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 6 at 4:34 AM |
| Sectoral Asset Management Inc Cuts Position in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 5 at 3:35 PM |
| USA Financial Portformulas Corp Buys New Holdings in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 5 at 3:04 PM |
| Abiomed Showcases Impella® Technology that Enables Heart Recovery at ACC with 25 Presentations
finance.yahoo.com - March 5 at 10:49 AM |
| ABIOMED, Inc. (ABMD) Holdings Trimmed by Schroder Investment Management Group
www.americanbankingnews.com - March 5 at 9:03 AM |
| ABIOMED, Inc. (ABMD) Shares Bought by UBS Asset Management Americas Inc.
www.americanbankingnews.com - March 4 at 10:46 AM |
| Maverick Capital Ltd. Invests $6.11 Million in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 3 at 2:06 PM |
| Brown Advisory Inc. Cuts Holdings in ABIOMED, Inc. (ABMD)
www.americanbankingnews.com - March 3 at 4:56 AM |
Abiomed (NASDAQ:ABMD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abiomed (NASDAQ:ABMD) Income Statement, Balance Sheet and Cash Flow Statement
Abiomed (NASDAQ ABMD) Stock Chart for Friday, April, 20, 2018
Loading chart…
